aTyr Pharma Presents Analyses of Resolaris Phase 1b/2 Trial in Patients with Limb Girdle Muscular Dystrophy 2B and Facioscapu...
April 24 2017 - 8:00AM
- Resolaris Demonstrated Favorable Safety Profile
and Promising Signals of Clinical Activity -
aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged
in the discovery and development of Physiocrine-based therapeutics
to address severe, rare diseases, today announced its participation
as part of the Emerging Science Platform Session at the upcoming
American Academy of Neurology (AAN) 69th Annual Meeting to be held
April 22 – 28, 2017 in Boston, MA.
Details of the session are below:
Emerging Science Platform Session: Tuesday, April 25,
2017 from 5:45 p.m. – 7:15 p.m. (ET)
- Title: Results of a Phase 1b/2 Study of
ATYR1940 in Adult Patients with Limb Girdle Muscular Dystrophy Type
2B (LGMD2B) and Facioscapulohumeral Muscular Dystrophy (FSHD)
(ATYR1940-C-004)
- Author and Presenter: John Vissing, M.D.,
Ph.D., Professor of Neurology, University of Copenhagen
- Supporting Authors: Attarian S., Gidaro T.,
Mozaffar T., Iyadurai S., Walker G., Shukla, S., Servais, L.,
Wagner, K.
- Location: Boston Convention and Exhibition
Center, 415 Summer St., Boston, MA
The poster presentation provides further detail on the
previously announced results from the completed Phase 1b/2
open-label, intra-patient dose escalation 004 trial testing doses
of Resolaris (ATYR1940) of up to 3.0 mg/kg biweekly in patients
with LGMD2B and FSHD. Data from all clinical trials completed to
date demonstrate that Resolaris has a favorable safety profile and
was generally well-tolerated across all doses tested. There have
been no observed signs of general immunosuppression and low-level
anti-drug antibody signals did not result in clinical symptoms. 78%
of the LGMD2B patients in the trial recorded increases in muscle
function at 14 weeks as measured by manual muscle test (MMT) score,
a validated assessment tool. 50% of the FSHD patients in the trial
recorded increases in muscle function as measured by MMT score.
aTyr believes these data are supportive of further advancement
of Resolaris.
About Resolaris™
aTyr Pharma is developing Resolaris as a potential
first-in-class intravenous protein therapeutic candidate for the
treatment of rare myopathies with an immune component. Resolaris is
derived from a naturally occurring protein released by human
skeletal muscle cells. aTyr believes Resolaris has the potential to
provide therapeutic benefit to patients with rare myopathies with
an immune component characterized by excessive immune cell
involvement.
About aTyr Pharma
aTyr Pharma is engaged in the discovery and clinical development
of innovative medicines for patients suffering from severe, rare
diseases using its knowledge of Physiocrine biology, a newly
discovered set of physiological pathways. To date, the company has
generated three innovative therapeutic candidate programs based on
its knowledge of Physiocrine biology in three different therapeutic
areas. aTyr has built an intellectual property estate, to protect
its pipeline, comprising over 175 issued patents or allowed patent
applications that are owned or exclusively licensed, including over
300 potential Physiocrine-based protein compositions. aTyr's key
programs are currently focused on severe, rare diseases
characterized by immune imbalance for which there are currently
limited or no treatment options. For more information, please visit
http://www.atyrpharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Litigation Reform Act.
Forward-looking statements are usually identified by the use of
words such as “anticipates,” “believes,” “estimates,” “expects,”
“intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,”
and variations of such words or similar expressions. We intend
these forward-looking statements to be covered by such safe harbor
provisions for forward-looking statements and are making this
statement for purposes of complying with those safe harbor
provisions. These forward-looking statements, including statements
regarding the potential and potential therapeutic benefits of
Resolaris™, the ability of the Company to successfully advance its
pipeline or product candidates, undertake certain development
activities (such as clinical trial enrollment and the conduct of
clinical trials) and accomplish certain development goals and the
timing of such activities and development goals, the timing of
initiation of additional clinical trials, the scope and strength of
our intellectual property portfolio, our ability to receive
regulatory approvals for, and commercialize, our product candidates
and of reporting results from our clinical trials reflect our
current views about our plans, intentions, expectations, strategies
and prospects, which are based on the information currently
available to us and on assumptions we have made. Although we
believe that our plans, intentions, expectations, strategies and
prospects as reflected in or suggested by those forward-looking
statements are reasonable, we can give no assurance that the plans,
intentions, expectations or strategies will be attained or
achieved. Furthermore, actual results may differ materially from
those described in the forward-looking statements and will be
affected by a variety of risks and factors that are beyond our
control including, without limitation, risks associated with the
discovery, development and regulation of our Physiocrine-based
product candidates, as well as those set forth in our most recent
Annual Report on Form 10-K for the year ended December 31, 2016 and
in our other SEC filings. Except as required by law, we assume no
obligation to update publicly any forward-looking statements,
whether as a result of new information, future events or
otherwise.
Contact:
Mark Johnson
Sr. Director, Investor Relations
mjohnson@atyrpharma.com
858-223-1163
aTyr Pharma (NASDAQ:LIFE)
Historical Stock Chart
From Mar 2024 to Apr 2024
aTyr Pharma (NASDAQ:LIFE)
Historical Stock Chart
From Apr 2023 to Apr 2024